4/A: Inmune Bio CFO David Moss Acquires Shares and Warrants in Registered Direct Offering

Inmune Bio's CFO, David Moss, purchased shares and warrants in a registered direct offering, amending a previous filing to correct a reporting error.

Summary

• David Moss, CFO, Treasurer, and Secretary of Inmune Bio, Inc., acquired 18,028 shares of common stock and warrants to purchase 18,028 shares in a registered direct offering on April 19, 2024.
• The transaction was executed at a price of $8.32 per share for the common stock.
• The warrants have an exercise price of $9.152 and were purchased for $0.125 each.
• The aggregate purchase price for the shares and warrants was $152,246.46.
• The warrants are exercisable immediately and expire two years from the initial exercise date or thirty trading days following the reporting of top-line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, with a potential extension for insiders during blackout periods.
• An amendment was filed on April 24, 2024, to correct an error in the original Form 4, clarifying that the transaction was a purchase rather than an award.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction with no overtly positive or negative implications. The CFO's purchase could be seen as a positive signal, but it's not a major event.

Positives

• The CFO's purchase of shares and warrants could be interpreted as a sign of confidence in the company's prospects.
• The registered direct offering provides the company with additional capital.

Risks

• The warrant expiration is tied to the reporting of top-line data from the Phase 2 Alzheimer's program, which introduces uncertainty regarding the timing of potential warrant exercises.
• Blackout periods could delay the exercise of warrants held by insiders.

Future Outlook

The warrant expiration is linked to the reporting of top-line data from the Phase 2 Alzheimer's program of XPro1595, which will influence the timing of potential warrant exercises.

Management Comments

• The reporting person purchased the securities in a registered direct transaction from the Company.

Industry Context

Registered direct offerings are a common method for small to mid-cap biotech companies to raise capital. Insider participation can be viewed positively by investors.

Comparison to Industry Standards

• Similar registered direct offerings in the biotech industry often involve the issuance of shares and warrants to institutional investors and company insiders.
• The pricing of the shares and warrants is typical for companies at Inmune Bio's stage of development.
• Comparable companies like Cassava Sciences (SAVA) and Anavex Life Sciences (AVXL), which are also focused on Alzheimer's treatments, have utilized similar financing strategies.

Stakeholder Impact

• Shareholders may view the CFO's purchase as a positive signal.
• The capital raised through the registered direct offering can support the company's research and development efforts.

Next Steps

• Potential exercise of warrants depending on the Phase 2 Alzheimer's program data release and blackout periods.

Key Dates